NDA 021999 · Janssen Pharms
Invega
Paliperidone · Oral · Atypical Antipsychotic
NovelLast checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Dec 19, 2006
Approved uses
5
Original approval plus efficacy supplements
Registered trials
186
60 Phase 3, 3 recruiting
FAERS reports
23,466
11,599 serious, 845 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning . Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Jan 31, 2025.
INVEGA is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 12–17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) Efficacy was established in two 6-week trials in adult patients. ( 14.2 ) 1.1 Schizophrenia INVEGA (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14.1) ] . The efficacy of INVEGA in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. 1.2 Schizoaffective Disorder INVEGA (paliperidone) Extended-Release Tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14.2) ] . The efficacy of INVEGA in schizoaffective disorder was established in two 6-week trials in adults.
Mechanism: Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone in schizophrenia is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor antagonism.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 6, 2011 Supplement 24 · Efficacy · priority review LetterLabel
- Jul 31, 2009 Supplement 13 · Efficacy · priority review LetterLabel
- Jul 31, 2009 Supplement 14 · Efficacy · priority review LetterLabel
- Dec 21, 2007 Supplement 1 · Efficacy LabelLetter
- Dec 19, 2006 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPediatric Medical Review
5 products under this application
- INVEGA · PALIPERIDONE 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- INVEGA · PALIPERIDONE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INVEGA · PALIPERIDONE 9MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INVEGA · PALIPERIDONE 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INVEGA · PALIPERIDONE 1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Paliperidone" as an intervention, any sponsor and status, largest first.
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT00460512 · 1,814 participants · Start Apr 25, 2007 · Primary completion Jan 22, 2009
Drug: Paliperidone ER · For: Schizophrenia
Sites: Antwerp, Belgium; Bertrix, Belgium; Dave, Belgium · 231 sites in all
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01515423 · 1,429 participants · Start May 2012 · Primary completion Feb 2015
Drug: PP3M 175 mg eq.; PP3M 263 mg eq. and 7 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Glendale, California; Long Beach, California · 174 sites in all
- Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00589914 · 1,221 participants · Start Mar 2007 · Primary completion Jun 2009
Drug: RISPERDAL CONSTA; Paliperidone palmitate · For: Schizophrenia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Cerritos, California · 82 sites in all
- Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaPivotal-lookingCompleted
Janssen PharmaceuticaJohnson & Johnson (Janssen) (JNJ)
NCT01662648 · 1,117 participants · Start Jun 2007 · Primary completion Apr 2008
Drug: Paliperidone ER · For: Schizophrenia
- Paliperidone Palmitate Flexible Dosing in SchizophreniaPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT01281527 · 1,044 participants · Start Nov 2010 · Primary completion Nov 2012
Drug: Paliperidone Palmitate · For: Schizophrenia
Sites: Salzburg, Austria; Brussels, Belgium; Dave, Belgium · 127 sites in all
- Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in SchizophreniaPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00439634 · 873 participants · Start Feb 2007 · Primary completion Sep 2009
Drug: AVE1625; placebo · For: Schizophrenia
Sites: Bridgewater, New Jersey; Laval, Canada
- A Study of Paliperidone Palmitate 6-Month FormulationPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03345342 · 841 participants · Start Nov 20, 2017 · Primary completion May 8, 2020
Drug: PP6M; PP3M 350 mg eq. and 2 more · For: Schizophrenia
Sites: Rogers, Arkansas; Anaheim, California; Costa Mesa, California · 138 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injury4,330
- gynaecomastia3,666
- drug ineffective1,795
- abnormal weight gain1,662
- off label use1,565
- weight increased1,390
- hyperprolactinaemia1,272
- galactorrhoea1,060
- sedation762
- dyskinesia717
- dystonia715
- treatment noncompliance684
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 696 |
| 2008 | 743 |
| 2009 | 650 |
| 2010 | 524 |
| 2011 | 687 |
| 2012 | 783 |
| 2013 | 652 |
| 2014 | 966 |
| 2015 | 2,359 |
| 2016 | 4,208 |
| 2017 | 3,453 |
| 2018 | 910 |
| 2019 | 847 |
| 2020 | 814 |
| 2021 | 812 |
| 2022 | 932 |
| 2023 | 924 |
| 2024 | 801 |
| 2025 | 1,024 |
| 2026 | 681 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invega (Paliperidone)
2024 spending
$2.3M
Beneficiaries
704
4,179 claims
Per beneficiary
$3,336
$13.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $122,657,282 |
| 2021 | $84,143,307 |
| 2022 | $25,750,207 |
| 2023 | $5,169,576 |
| 2024 | $2,348,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
Schneider-Thoma J, Chalkou K, Dörries C, et al. · Lancet 2022 · Systematic Review, Network Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.